Expand all sections

sofosbuvir / velpatasvir

Epclusa

Extended indication Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged
Therapeutic value No estimate possible yet
Registration phase Positive CHMP opinion

Product

Active substance sofosbuvir / velpatasvir
Domain Infectious diseases
Reason of inclusion Indication extension
Main indication Viral infections other
Extended indication Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 3 years of age and older.
Proprietary name Epclusa
Manufacturer Gilead
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)
Additional remarks Werkingsmechanisme: sofosbuvir (NS5B-remmer), velpastasvir (NS5A-remmer)

Registration

Registration route Centralised (EMA)
Submission date 2021
Expected Registration January 2022
Registration phase Positive CHMP opinion
Additional remarks Positieve CHMP-opinie in november 2021.

Therapeutic value

Therapeutic value No estimate possible yet
Substantiation Betreft een uitbreiding voor kinderen.
Dosage per administration 400/100MG

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

References medicijnkosten.nl
Additional remarks Gemiddelde prijs betreft €321,16 inclusief btw en exclusief afleverkosten.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.